DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.43
-0.54 (-5.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.97
Open9.90
Bid9.26 x 1000
Ask11.22 x 2200
Day's Range9.35 - 9.96
52 Week Range6.00 - 15.48
Volume341,398
Avg. Volume2,055,540
Market Cap506.086M
Beta (3Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire5 days ago

    Dermira to Present at the Raymond James Life Sciences and MedTech Conference

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present at the Raymond James Life Sciences and MedTech Conference in New York on June 18, 2019 at 2:25 p.m. ET. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.

  • Business Wirelast month

    Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update

  • Business Wire2 months ago

    Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended March 31, 2019 and provide an operational update after market close on Tuesday, May 7, 2019. Dermira also has early-stage research and development programs in other areas of dermatology.

  • Business Wire2 months ago

    Dermira to Present at the 18th Annual Needham Healthcare Conference

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:50 p.m. ET. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products.

  • GlobeNewswire3 months ago

    Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the launch of “Life Unfolds,” a new direct-to-consumer creative campaign designed to generate awareness of QBREXZA™ (glycopyrronium) cloth as a potential treatment option for people living with primary axillary hyperhidrosis, commonly known as excessive underarm sweating. QBREXZA, the first and only, once-daily, topical prescription anticholinergic, is approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

  • GlobeNewswire3 months ago

    Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    MENLO PARK, Calif., March 22, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire3 months ago

    Dermira Prices $130.0 Million Public Offering of Common Stock

    MENLO PARK, Calif., March 19, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire3 months ago

    Dermira Announces Proposed Public Offering of Common Stock

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it intends to offer $110.0 million of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase up to an additional $16.5 million of its common stock in the offering. All of the shares will be offered and sold by Dermira. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities are acting as book-runners for the offering.

  • GlobeNewswire3 months ago

    Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis. All three doses of lebrikizumab met the primary endpoint, demonstrating greater improvements in the Eczema Area and Severity Index (EASI) score compared to placebo. The safety profile for lebrikizumab observed in the study was consistent with prior studies evaluating this investigational therapy.

  • GlobeNewswire3 months ago

    Dermira to Present at the Cowen and Company 39th Annual Health Care Conference

    MENLO PARK, Calif., March 05, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire4 months ago

    Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis

    Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary.

  • GlobeNewswire4 months ago

    Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 millionOver 14,500 prescriptions for QBREXZA written in first three months of launchSecured QBREXZA coverage for.

  • ACCESSWIRE4 months ago

    Dermira Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Dermira Inc (NASDAQ: DERM ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 4:30 PM Eastern ...

  • GlobeNewswire4 months ago

    Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced that new post-hoc analyses from its glycopyrronium tosylate (QBREXZA™ (glycopyrronium) cloth) clinical program will be presented in poster format at the 77th Annual Meeting of the American Academy of Dermatology (AAD) being held in Washington, D.C., March 1-5, 2019. Poster presentations will highlight post-hoc data analyses from the Phase 3 clinical trials evaluating glycopyrronium tosylate in patients 9 years and older with primary axillary hyperhidrosis, commonly referred to as excessive underarm sweating.

  • GlobeNewswire4 months ago

    Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today the initiation of a proof-of-concept study that will evaluate the efficacy and safety of QBREXZA™ (glycopyrronium) cloth in people living with primary palmar hyperhidrosis (excessive sweating of the hands). QBREXZA is a once-daily, prescription anticholinergic that was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with primary axillary hyperhidrosis, a medical condition commonly referred to as excessive underarm sweating.

  • GlobeNewswire4 months ago

    Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    MENLO PARK, Calif., Feb. 21, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire4 months ago

    Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019

    MENLO PARK, Calif., Feb. 19, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire4 months ago

    Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab

    Almirall, S.A. (BME:ALM) and Dermira, Inc. (DERM) announced today that the companies have entered into an option and license agreement under which Almirall has acquired an option to exclusively license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. In exchange, Dermira will receive an upfront option fee of $30 million.

  • GlobeNewswire6 months ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on December 10, 2018, the company granted inducement awards to four new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 2,575 shares of Dermira common stock and stock options to purchase an aggregate of 14,100 shares of Dermira common stock.

  • GlobeNewswire6 months ago

    Dermira Enters into Credit Facility with Athyrium Capital Management

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the closing of a $125 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare-focused investment firm. “We are pleased to be partnering with Athyrium,” said Andrew Guggenhime, chief financial officer of Dermira. “This credit facility provides us additional financial flexibility to advance our business with a focus on the ongoing launch of QBREXZA for primary axillary hyperhidrosis and the lebrikizumab program for moderate-to-severe atopic dermatitis.

  • GlobeNewswire7 months ago

    Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire7 months ago

    Dermira to Present at Evercore ISI HealthCONx Conference

    MENLO PARK, Calif., Nov. 19, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire7 months ago

    Dermira Reports Third Quarter 2018 Financial Results

    Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to.

  • GlobeNewswire7 months ago

    Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018

    MENLO PARK, Calif., Oct. 31, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.